Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
33.8M
-
Shares change
-
+1.09M
-
Total reported value, excl. options
-
$1.02B
-
Value change
-
+$33.1M
-
Number of buys
-
32
-
Number of sells
-
-14
-
Price
-
$30.24
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q2 2020
59 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q2 2020.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.8M shares
of 120M outstanding shares and own 28.11% of the company stock.
Largest 10 shareholders include FRAZIER MANAGEMENT LLC (10.5M shares), FMR LLC (5.72M shares), ORBIMED ADVISORS LLC (4.67M shares), Bain Capital Life Sciences Investors, LLC (3.98M shares), BlackRock Inc. (1.57M shares), Vivo Capital, LLC (1.29M shares), RA CAPITAL MANAGEMENT, L.P. (1.17M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.07M shares), Omega Fund Management, LLC (845K shares), and WELLS FARGO & COMPANY/MN (527K shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.